Towards Personalized Cancer Medicine

迈向个性化癌症医学

• 批准号: 7805025
• 负责人: JOAN MASSAGUE
• 金额: $ 1.5万
• 依托单位: NEW YORK ACADEMY OF SCIENCES
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7805025
• 关键词: Academia; Academy; Address; Area; Award; Bioinformatics; Cancer Biology; Cancer Patient; Caring; Cellular biology; Clinical; Clinical Treatment; Clinical Trials; Collaborations; Data; Development; Diagnosis; Discipline; Disease; Doctor of Philosophy; Electronics; Elements; Epigenetic Process; Event; Family; Fees; Fostering; Friends; Future; Genetic; Genetic Programming; Genomics; Goals; Grant; Health; Industry; Institutes; Interdisciplinary Study; Interest Group; International; Knowledge; Life; Malignant Neoplasms; Medical Research; Medicine; Museums; National Cancer Institute; Nature; New York; Participant; Physicians; Predisposition; Prevention; Principal Investigator; Printing; Proteomics; Research; Research Personnel; Research Training; San Francisco; Science; Scientist; Translations; Travel; University Hospitals; Work; abstracting; anticancer research; base; cancer care; cancer imaging; cancer therapy; clinical care; drug development; experience; health care service organization; improved; lectures; meetings; member; mouse model; multidisciplinary; oncology; outcome forecast; posters; programs; response; success; symposium; therapy development; tumor; tumor molecular fingerprint

DESCRIPTION (provided by applicant): The New York Academy of Sciences is planning a landmark international program, "Towards Personalized Cancer Medicine", to explore the personalization of cancer predisposition, diagnosis, prognosis, treatment, and therapy development. The principal investigator for this grant is Dr. Joan Massagu?, Chair of the Cancer Biology and Genetics Program in the Sloan-Kettering Institute, New York. The program will include a 3-day live symposium (to be held in May 2010 in Barcelona) and the development of high-quality print and electronic enduring materials to disseminate the scientific information exchanged by the conference participants. It is very timely that the plethora of data emerging from the molecular signatures of cancers is shared across disciplines to identify the steps toward to the effective personalization (individualization) of cancer medicine. The main goals of this program are: 1) to foster dialogue among basic and clinical scientists working in areas of cancer research and oncology leading to a personalized treatment of malignant tumors; and 2) to generate comprehensive and cross-disciplinary approaches for the translation of personalized cancer research into individualized clinical treatments for cancer. We anticipate an advancement in cancer research and clinical therapy personalization to result from the discussions, enduring materials, and collaborations generated at this meeting. Cancer patients will benefit from discoveries and approaches resulting from this symposium, which is in perfect line with The National Cancer Institute's commitment to supporting research, training and health information relevant to the cause, diagnosis, prevention, and treatment of cancer, and to the care of cancer patients and their families. To achieve these goals, the conference will incorporate a combination of plenary lectures, a keynote address, and several elements to encourage networking and audience participation, and to highlight promising young scientists. The program will include a panel discussion, poster and short presentations selected from submitted abstracts, networking breaks, a conference reception, and the availability of travel awards. The conference will attract wide participation (250 attendees) among senior and young scientists, clinicians, and physicians working in the fields of genomics, bioinformatics, proteomics, genetics, epigenetics, cell biology, mouse models of cancer, imaging, drug development, and clinical trials, among others. In addition, we expect this group to include people from academia, industry, regulatory agencies, health care organizations, and other groups interested in the individualized targeting of cancer medicine.

描述（由申请人提供）：纽约科学院正在计划一项具有里程碑意义的国际计划，“走向个性化癌症医学”，以探索癌症易感性、诊断、预后、治疗和疗法开发的个性化。本基金的主要研究者是琼·马萨古博士，纽约斯隆-凯特琳研究所癌症生物学和遗传学项目主席。该计划将包括一个为期3天的现场研讨会（将于2010年5月在巴塞罗那举行）和高质量的印刷和电子持久材料的开发，以传播与会者交流的科学信息。 从癌症分子特征中产生的大量数据在各个学科之间共享，以确定癌症医学有效个性化（个体化）的步骤，这是非常及时的。该计划的主要目标是：1）促进在癌症研究和肿瘤学领域工作的基础和临床科学家之间的对话，从而实现恶性肿瘤的个性化治疗; 2）产生全面和跨学科的方法，将个性化癌症研究转化为癌症的个性化临床治疗。 我们预计，癌症研究和临床治疗个性化的进步将从这次会议上产生的讨论，持久的材料和合作中产生。癌症患者将受益于本次研讨会的发现和方法，这完全符合美国国家癌症研究所的承诺，即支持与癌症的病因、诊断、预防和治疗以及癌症患者及其家属的护理相关的研究、培训和健康信息。 为了实现这些目标，会议将结合全体讲座，主旨演讲和几个元素，以鼓励网络和观众的参与，并突出有前途的年轻科学家。该计划将包括一个小组讨论，海报和简短的演讲，从提交的摘要，网络休息，会议招待会，并提供旅行奖励。会议将吸引在基因组学、生物信息学、蛋白质组学、遗传学、表观遗传学、细胞生物学、癌症小鼠模型、成像、药物开发和临床试验等领域工作的高级和年轻科学家、临床医生和医生的广泛参与（250名与会者）。此外，我们希望这个小组包括来自学术界、工业界、监管机构、医疗保健组织和其他对癌症药物个体化靶向感兴趣的团体的人员。